Predictive Value of Air Pollution and Metabolomics for Gastric Cancer.

NCT06641700 | Active Not Recruiting DMC

• 1 other identifier: 2024-221-02
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

As one of the common malignant tumours worldwide, gastric cancer continues to have a high incidence and mortality rate, especially in Asia. Although a large number of studies have focused on its underlying genetic and lifestyle factors, the specific role of environmental factors in gastric cancer development and progression has not been fully elucidated. Air pollution, a growing environmental problem, and its major components such as PM2.5, PM10, and NO2 have been shown to be closely associated with the occurrence and development of many chronic diseases. Recent studies have gradually revealed the association between air pollution and certain cancer types (e.g., lung cancer), but its relationship with gastric cancer remains relatively unexplored. Against this background, the application of metabolomics provides new perspectives and methods to study the association between gastric cancer and environmental factors. Metabolomics is capable of systematically analysing the metabolite composition and changes in individuals under different environmental exposures, revealing the potential effects of environmental factors, such as air pollution, on individual metabolic functions. By combining air pollution data and metabolomics analysis, investigators can deeply explore the role of environmental factors in the occurrence, development and prognosis of gastric cancer, and thus provide a scientific basis for the development of prevention and treatment strategies.

Conditions

Gastric Cancers

Keywords

gastric cancer; environment; air pollution; metabolomics; gut microorganisms

Outcome Measures

Primary Outcomes (1)

• Rate of postoperative complications

  Surgical complications was defined as any postoperative complication occurring during the postoperative hospitalisation period.

  From date of surgery until the date of first documented postoperative complication, assessed up to 2 months after surgery.

Secondary Outcomes (1)

• Overall survival

  From date of diagnosis until the date of death from any cause or or loss to follow-up, whichever came first, assessed up to 60 months

Study Arms (2)

the gastric cancer group

Pre-operative gastric cancer diagnosed by pathological biopsy in our clinic.

Diagnostic Test: diagnosed with gastric cancer

the contol group

Adults with no history of malignancy and willing to participate in this study.

Interventions

diagnosed with gastric cancer DIAGNOSTIC_TEST

Pathological biopsy confirmed the diagnosis of gastric cancer.

the gastric cancer group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All adult patients diagnosed with gastric and undergoing radical surgery for gastric cancer at the study centre may be included in the gastric cancer group.

You may qualify if:

• Diagnosis of gastric cancer confirmed by pathology or cytology;
• aged \>18 years;
• not received chemotherapy, radiotherapy, targeted therapy or immunotherapy;
• post-operative pathological stages other than stage IV, or no liver, lung or other organs as confirmed by CT, MRI, B-ultrasound imaging.

You may not qualify if:

• Patients with systemic diseases such as severe cardiorespiratory insufficiency affecting the choice of treatment regimen;
• inappropriate for enrolment as assessed by the investigator;
• incomplete clinical data.

Sponsors & Collaborators

• Dong Peng: lead

Study Sites (1)

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400016, China

Location

MeSH Terms

Conditions

Stomach Neoplasms

Interventions

Diagnosis

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: October 13, 2024
• First Posted: October 15, 2024
• Study Start: October 1, 2024
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2029
• Last Updated: October 16, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)